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Background: While fluid overload (FO) and alterations in the autonomic nervous system (ANS) such as
hypersympathetic activity, are known risk factors for cardiovascular morbidity and mortality in patients on chronic
hemodialysis (HD), their relationship has not been thoroughly studied.
Methods: In this observational study involving 69 patients on chronic HD, FO was assessed by whole body
bioimpedance measurements before the midweek HD session and ANS activity reflected by Heart Rate
Variability (HRV) was measured using 24-hour Holter electrocardiogram recordings starting before the same HD
treatment. In total, 13 different HRV indices were analyzed, comprising a mixture of time domain, frequency
domain and complexity parameters. A correlation analysis was performed between the HRV indices and
hydration status indices. Successively, patients were retrospectively assigned to a high FO (H, FO > 2.5 L) or low
FO (L, FO ≤ 2.5 L) group and these were further compared also after stratification by diabetes mellitus. Finally, a
small number of patients without diabetes with significant and persistent FO were followed up for 3 months
post-study to investigate how normalization of fluid status affects HRV.
Results: SDANN, VLF, LZC and HF% parameters significantly correlate with FO (correlation coefficients were
respectively r = –0.40, r = –0.37, r = –0.28 and r = 0.26, p-value < 0.05). Furthermore, LF% and LF/HF were
inversely correlated with hydration status (correlation coefficients were respectively r = –0.31 and r = -0.33,
p-value < 0.05). These results indicate an association between FO and reduced HRV, higher parasympathetic
activation and reduced sympathetic response to the HD session. Indeed, group H tended to have lower values
of SDANN, VLF and LZC, and higher values of HF% than patients in the L group. Finally, there was a trend
towards lower LF% measured during the last 30 minutes of HD for the H group versus the L group. Reduction
in FO achieved over 3 months by implementation of a strict fluid management plan resulted in an increase
of HRV.
Conclusions: Our results suggest that depressed HRV is associated with fluid overload and that normalization
of hydration status is accompanied by improved HRV.
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End stage renal disease (ESRD) patients are known to
have a higher risk of mortality than the healthy popula-
tion. Cardiovascular events are a major cause of this
high mortality, more than 40% of all patients with ESRD
die of cardiac causes [1]. Fluid overload (FO) is com-
mon in patients on maintenance hemodialysis (HD) and
it can lead to hypertension, left ventricular hypertrophy
and cardiac mortality [2]. Even though the genesis of
LVH is multifactorial, hypertension and FO are prominent
factors of particular relevance for patients on HD [3]. An
abnormal hydration state has been related not only to LVH
and hypertension, but also to dialysis related hypotension,
pulmonary and peripheral edema, heart failure and other
adverse cardiovascular events [4-6]. Moreover, FO has also
been highlighted as a key independent predictor of mortal-
ity in patients on HD [7].
Alterations in the autonomic nervous system (ANS) are
also associated with cardiovascular death [8,9], e.g. auto-
nomic neuropathy in patients with diabetes and chronic
kidney disease (CKD) [10]. Sympathetic overactivity and
parasympathetic blunting have been observed in patients
with CKD and ESRD [11,12]. This sympatho-vagal imbal-
ance contributes to the increased risk of cardiac death in
these populations [10]. Heart rate variability (HRV), which
reflects the ability of the sinoatrial node to change heart
rate in response to sympathetic and parasympathetic in-
puts, is a valuable tool for assessing heart rate control and
also allows quantification of autonomic activity [10]. For
instance, the spectral decomposition of HRV signals has
been proved to provide valuable indices: the high fre-
quency (HF) power reflects vagal and respiratory mediated
changes in heart rate, whereas low frequency (LF) power
is mostly a marker of sympathetic modulation [13].
Although alterations of the ANS and high FO are each
recognized risk factors for increased cardiovascular mor-
tality in patients on HD, the effects of fluid overload on
the ANS in the ESRD population have not yet been fully
elucidated.
The effects of changes in central volumes on ANS are of
great interest also from a physiological point of view and
many studies have been performed on this topic [14,15].
The hypothesis of the work is based on the fact that auto-
nomic nervous system (ANS) is known to be affected by
variations of central volumes as it proved from different
physiological studies, e.g. protocols of lower body negative
pressure (LBNP) [16], rest-tilt [17] and head down tilt bed
rest [18]. In fact, a critical decrease in left ventricular filling,
due to the decreased venous return, induce a sympathetic
activation mediated by cardiopulmonary baroreceptor [19],
and the sympathetic activations is also influenced by the
hydration status [15].
The aim of this study is to investigate the relationship
between fluid overload and alterations of the ANS inpatients on chronic HD using FO measurements from
the Body Composition Monitor (BCM, Fresenius Med-
ical Care) and using indices of HRV as markers for ANS
activity. Furthermore, as diabetes has a negative effect
on the ANS, results for patients with and without dia-
betes are also analyzed separately. A small group of
non-diabetic patients with persistent and high FO was
selected for studying the effect of reducing FO on HRV
over a 3 month follow-up period, the objective is to ob-
serve if ANS markers provided by HRV analyses can be
modified and improved by reducing FO, in particular
to observe if the low HRV and high sympathetic activ-
ity can be reversed by reducing FO.
Methods
Study design & setting
Eighty patients on chronic HD receiving treatment at the
San Bortolo Hospital, Vicenza, Italy were enrolled in this
observational study between April 1, 2009, and October
30, 2009.
Participants
Inclusion criteria were age above 18 years and HD vin-
tage of at least 6 months. Exclusion criteria were a HD
frequency other than thrice weekly and hospitalization
or antibiotic treatments in the preceding 8 weeks. The
Institutional Review Board of San Bortolo Hospital ap-
proved the study. Patients signed informed consent prior
to enrollment and the study was conducted in full ac-
cordance with the Declaration of Helsinki.
Clinical data and study size
Whole body bioimpedance spectroscopy was done just be-
fore the midweek HD session. 24 hour-ECG Holter was
started prior to the same midweek HD. The patients were
retrospectively classified by degree of FO into two groups:
group H encompassed patients with FO > 2.5 L (high FO)
and group L encompassed patients with FO ≤ 2.5 L (low
FO). This threshold was chosen based on studies indicat-
ing an increased mortality in patients with FO > 2.5 L
[20,21]. H and L groups were successively compared after
stratification by diabetes mellitus. Four groups were thus
considered: diabetics with high (Hd) and low FO (Ld),
non- diabetics with high (Hnd) and low FO (Lnd). Figure 1
provides an overview of the study design and the patient
numbers in each of the four groups.
The investigation results were subsequently tested by
exploring if reductions in FO can favorably influence
HRV. To this end, a small number of non-diabetic patients
(5) with significant and persistent FO (i.e. FO > 3 L in the
last 3 months) and who signed informed consent were en-
rolled in a subsequent 3-month fluid management plan
from October 2010 and May 2011. A FO of < 2.5 L was
targeted for the end of the first month; this level was then
HD patients in study according to 
inclusion/exclusion criteria
N=80  
H Group 
 (FO > 2.5 L) 
N=38 
Hd Group 
(diabetic) 
N=8 
*Robusteness of results checked in subset of this group
with FO > 3L for last 3 months and willing to participate 
in 3-month follow-up (N=5) 
Drop out due to
persistent arrhythmias
orshort ECG reading
time 
N=11  
Patients starting study 
N=69 
L Group 
(FO  2.5 L)              
N=31 
Hnd Group 
(non-diabetic) 
N=30 
*
Ld Group 
(diabetic) 
N=11 
Lnd Group 
(non-diabetic) 
N=30 
Figure 1 Study flow chart.
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Holter recordings were performed, as described before,
at the start of the study (baseline, BL), after 1 month
(1 M), when the target was supposed to be reached, and
after 3 months (3 M).
No changes in medication and drug prescription were
made during the study or during the 3-month post-
study follow-up.
Measurements
To determine the hydration state, clinical surrogate param-
eters are always considered, such as interdialytic weight
gain, ultrafiltration rate or blood pressure, or concepts are
subjectively invoked to define normal hydration, e.g. the
achievement of target dry weight without hypotensive epi-
sodes or interdialytic hypertension. Here, a whole body
bioimpedance spectroscopy method was employed. Before
each HD treatment, FO was assessed by the Body Compos-
ition Monitor (BCM, Fresenius Medical Care, Germany).
This measures the impedance between 5 and 1000 kHz.
High-frequency current passes through the total body water
(TBW), whereas low-frequency current cannot penetrate
cell membranes and thus flows exclusively through the
extracellular water (ECW). ECW consists of the interstitial
water, the plasma water and the transcellular water. Fluid
status is defined in terms of excess extracellular water using
physiologic models [22,23]. The BCM provides the FO
expressed in liters [7].
In addition to absolute FO just before the HD session
(FOpre), an additional parameter was measured: FOnormalized over the extracellular water (FOpre/ECW%).
FOpre/ECW% facilitates comparison between patients,
which may have the same FO value but a completely differ-
ent distribution of fluids; in particular this index is thought
to reflect the extent of central volumes accumulation.
Twenty four-hour electrocardiogram (ECG) Holter re-
cordings were started before the HD treatment employing
a three-lead Holter device with a sampling rate of 250 Hz
(clickholter, Cardioline, et medical devices SpA, Italy).
Eleven patients dropped out of the study for reasons re-
lated to the HRV analysis: presence of persistent arrhyth-
mias during HD, or duration of recording shorter than the
HD session for technical reasons, e.g. detachment of the
electrodes.
In addition, systolic blood pressure (SBP), diastolic
blood pressure (DBP), pulse pressure (PP), and FO were
collected during the post-study three-month follow up in-
volving 5 patients. These parameters were recorded during
the HD treatments in the same week of ECG recording
and the average values were considered for the analysis.
During first month, FO reduction was performed by de-
creasing the post-dialysis weight treatment-by-treatment
in steps defined by the attending nephrologist. The post-
dialysis fluid status was assessed by subtracting the intra-
dialytic weight loss from the pre-dialysis FO measurement.
The time-averaged fluid overload (TAFO) was calculated
as the mean between the pre-dialysis and the post-dialysis
fluid status, thus assuming a linear accumulation of fluid
in the interdialytic period. Weekly targeted post-dialysis
weight was defined individually so that it translated to a
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from several dialysis units, and considered reachable and
tolerated for all patients, even thought post-dialysis FO
values can be negative. Thus, the FO was reduced accord-
ing to the target of < 2.5 L after one month and this level
was then maintained in the two successive months.
HRV analysis
HRV refers to the variability of the duration between two
consecutive R peaks in electrocardiograms. The R peaks
were automatically identified and classified from the Holter
ECG recordings (CubeHolter, Cardioline, et medical devices
SpA, Italy). The obtained RR time series was subdivided
into 5-minute epochs. Epochs with at least 85% of qualified
sinus beats were considered and the so-called normal-to-
normal (NN) intervals, i.e. all intervals between adjacent R
peaks resulting from sinus node depolarization, were ana-
lyzed [24]. Mean values of 13 time domain, frequency do-
main and complexity indices were calculated for the first
30 minutes and last 30 minutes of HD, and for the entire
HD session, to represent the initial response of the patient
to HD, the final condition and an overall response during
treatment, respectively. The time domain parameters were:
mean NN intervals, the standard deviation of the NN in-
tervals (SDNN), the standard deviation of the averages of
NN intervals in all 5-minute segments of the recording
(SDANN). The frequency domain parameters were: auto-
regressive power spectral analysis in the very low fre-
quency (VLF, 0.003 < f ≤ 0.04 Hz), the low frequency (LF,
0.04 < f ≤ 0.15Hz) and the high frequency (HF, 0.15 < f ≤
0.4 Hz) bands, the LF/HF ratio and the normalized power
LF% calculated as LF/(total power – VLF) × 100 and the
normalized power HF% calculated as HF/(total power –
VLF) × 100 [24]. Regarding complexity domain parame-
ters, for each 5-minute epoch, the complexity of the sig-
nals was estimated by the Lempel Ziv complexity (LZC)
after the RR time series was encoded into a string. In this
work binary and ternary coding rules were adopted and
the coding factor p was 0.01 and 0.05. Full details for the
computation are described in [25].
Statistical analyses
Lilliefors test was used to test that data come from a nor-
mally distributed population. According to the test for
normal distribution, the correlation between the HRV in-
dices and FO parameters was analyzed by the Pearson or
Spearman rank test, respectively. The same analyses were
repeated by separating diabetic from non-diabetic patients.
The comparison between the HRV indices of the two
groups H and L was performed by Student’s test or
Mann–Whitney–Wilcoxon test. Categorical variables
were expressed as number, and comparisons between
groups were performed using Fisher’s Exact test. When
the two groups were subdivided into two subsets eachaccording to diabetes (Hd and Hnd, Ld and Lnd), one-way
ANOVA was performed to identify differences between
groups and post-hoc comparisons were performed by
Tukey’s least significant difference (LSD) test.
In the post-study 3-month results-exploratory phase,
HRV indices, FO and blood pressure data were analyzed
by one-way ANOVA for repeated measurements. Com-
parisons with baseline values were performed in a paired
fashion, by means of the Wilcoxon signed rank test and
the Student test and by using Bonferroni correction.
Continuous variables are expressed as means ± standard
deviation, or as medians with 25° and 75° percentiles. A p-
value < 0.05, 2-tailed, was considered statistically significant.
Results
Participants & descriptive data
A complete set of Holter recordings and reliable BCM
measurements were available for 69 patients who com-
pleted the study (Figure 1). Table 1 reports the data for the
two groups of patients: patients with high FO (group H,
FOpre >2.5 L) and with lower FO (group L, FOpre ≤2.5 L).
Notice that no severely obese or severely underweight pa-
tients are present in the current study (see BMI in Table 1).
The patients enrolled in this study were pretty stable and
their clinical history did not include hypotension prone-
ness. We reported also the HD related events, such as
cramps or dizziness, experienced by the patients after the
dialysis treatment only, so did not affect the treatment ad-
ministration. Patients in group L reported a shorter HD
vintage compared to group H only. Sixty-seven patients
(97%) were classified as hypertensive according to drug
prescription and/or blood pressure values.
Correlation analysis and comparisons of patients
stratified according to FO
Analysis of the correlation between all 13 HRV indices
and the two FO parameters was conducted. For clarity,
only those correlations yielding statistically significant re-
sults are presented in Table 2 for the 69 patients. HRV es-
timated during the all three times (i.e. first 30 mins, last 30
mins and entire HD session) showed a significant negative
correlation (SDANN, VLF and LZC parameters) with hy-
dration status parameters, while a significant positive cor-
relation (HF%) was observed for the first 30 mins and the
entire HD session. Furthermore, LF% and LF/HF were in-
versely correlated with the FO/ECW% for the last 30 mins
of HD (Figure 2). The magnitudes of these HRV values and
those for the entire HD session are provided in Table 3, as
are the respective values according to FO group and ac-
cording to diabetes status. In general, patients in group H
tended to have lower values of SDANN, VLF and LZC, and
higher values of HF% than patients in the L group, whereby
the differences for SDANN reached statistical significance
for Hd versus Ld and for Hnd versus Lnd. Finally, there
Table 1 Patient data
FOpre ≤ 2.5 L
(L group)
FOpre > 2.5 L
(H group)
P
N 31 38
FO [L] 1.1 (0.55, 1.6) 3.4 (2.8, 4.4) <0.001
FO/ECW% 7.0 (3.6, 9.3) 17.7 (15.7, 25.3) <0.001
Diabetes 11 8 0.2
Age [years] 65 (50,75) 69 (60, 75) 0.2
Gender [m/f] 18/13 27/11 0.3
Dialysis vintage [years] 4 (2, 7) 7 (5, 11) 0.02
Patients with residual
renal function
0 1 0.9
Treatment time [min] 236 (233, 241) 237 (234, 241) 0.5
UFR [L/hr] 0.67 (0.47, 0.84) 0.81 (0.56, 0.9) 0.2
UFR [ml/kg BW/h] 9.5 (5.9, 10.9) 10.9 (8.0, 13.6) 0.1
Dry body weight [kg] 74.2 (61.6, 78.6) 68.4 (61.0, 74.5) 0.2
BMI 26.4 (23.5, 28.8) 24.3 (21.6, 26.7) 0.2
Treatment modality
[HDF-OL/HD/HFD/HF]
3/26/2/0 6/27/3/2 0.6
HD related episodes
(cramps, dizziness,
hypotension)
5 6 0.9
Left ventricular hypertrophy 21 25 0.9
Peripheral vascular disease 17 12 0.8
Coronary heart disease 10 11 0.2
Hypertension 31 36 0.5
β-blockers 10 14 0.8
ACE inhibitors 9 11 0.8
Calcium antagonist 14 16 0.9
The values are expressed as median (25°, 75° percentiles) or numbers
of patients.
HDF-OL: Hemodiafiltration OnLine; HD:Hemodialysis; HFD: High Flux Dialysis;
HF: Hemofiltration.
Significant differences are indicated in bold.
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last 30 minutes of HD for the H group versus the L
group (L group: LF% = 42 (29,54); H group: LF% = 32
(17,50), p-value = 0.07).
Regarding differences due to diabetic status, statisti-
cally significant correlations were only observed with
non-diabetic patients. SDANN in non-diabetic subjects
was significantly correlated with FOpre/ECW% for all
time periods (during first 30 min of HD: r = -0.48, p-
value = 0.001; during last 30 min of HD: r = -0.32, p-
value = 0.04; during entire HD: r = -0.33, p-value = 0.03)
Moreover, LF%, LZC(2,0.01) and LZC(2,0.005), esti-
mated during the last 30 min of HD, were inversely cor-
related with FOpre/ECW% (LF%: r = -0.43, p-value =
0.006; LZC(2,0.01): r = -0.35, p-value = 0.03; and LZC
(2,0.005): r = -0.34, p-value = 0.03) (Figure 3).Post-study follow-up
Five non-diabetic patients with persistent FO > 3 L were
enrolled in the 3-month follow up program (Table 4). FO
decreased significantly both after one month and after
three months compared to baseline (BL: 3.78 ± 0.76 L,
1 M: 2.54 ± 0.49 L, 3 M: 2.23 ± 0.64 L, one-way ANOVA
for repeated measurements p-value = 0.001, paired t-test
with Bonferroni correction p-value = 0.02 between BL and
1 M, and between BL and 3 M values). Diastolic Blood
Pressure (DBP) decreased after 3 months from the begin-
ning of the study (BL: 79.9 ± 9.4 mmHg, 3 M: 71.2 ±
9.1 mmHg, one-way ANOVA for repeated measurements
p-value = 0.06), while changes in Systolic Blood Pressure
were not significant (BL: 153.4 ± 8.4 mmHg, 3 M: 146.6 ±
15.9 mmHg).
SDANN values for the entire HD session increased in
all 5 patients (paired Wilcoxon signed test p-value =
0.06). LF and LF% assessed during the HD session de-
creased in 4 out 5 patients, in particular, in patients 223
and 2400 with the highest baseline values (Table 5). Only
one patient (ID = 6794) displayed a different trend as he
was characterized by very low values of LF and LF% at
baseline, but after 3 months LF and LF% reached similar
values to the other patients.
Discussion
FO and alterations in the ANS are associated with in-
creased risk of cardiovascular mortality in CKD 5 patients.
To the best of our knowledge, this is the first study in pa-
tients on chronic HD to quantify the relationship between
fluid status and ANS, as assessed by HRV.
Several studies have shown that time- or frequency-
domain measures of HRV may predict mortality and non-
fatal arrhythmic events in patients with coronary heart
disease [26,27]. Moreover, a reduced HRV has been con-
sistently observed in patients with cardiac failure as well
[28,29].
A significant increase in SDANN index, which reflects an
increase in HRV, has been described in patients with mod-
erate to severe heart failure after cardiac resynchronization
therapy [30]. Noteworthy, lack of increase in SDANN four
weeks after resynchronization therapy identified patients at
highest risk for major cardiovascular events and no signifi-
cant improvement in left ventricular ejection fraction, on
the other hand, an increase of SDANN was associated with
short-term improvements of functional heart capacity
and of ANS modulation [30]. A decrease in complexity
indices of HRV was associated as well with cardiovascu-
lar disease [31,32].
Large prospective ESRD cohort studies are lacking [33],
and the results presented in this work can be compared
mainly with data from studies on cardiovascular popula-
tions. In fact, the studies on HRV in ESRD patients are
mainly focused on cardiac death stratification [34], to
Table 2 Correlation coefficients
First 30′ HD Last 30′ HD Entire HD
FO FO/ECW% FO FO/ECW% FO FO/ECW%
SDANN -0.40* -0.39* -0.29# -0.35* -0.31# -0.30*
VLF -0.37* -0.39* -0.25 -0.27# -0.25# -0.28*
LF% -0.09 -0.11 -0.33# -0.37† -0.17 -0.16
HF% 0.28# 0.29# 0.13 0.17 0.19 0.30§
LF/HF -0.21 -0.22 -0.31# -0.34# -0.22 -0.22
LZC (2,0.01) -0.18 -0.17 -0.17 -0.2 -0.13 -0.23
LZC (2,0.05) -0.23 -0.26§ -0.15 -0.30§ -0.07 -0.1
LZC (3,0.01) -0.26# -0.26# -0.34 -0.31# -0.29# -0.27#
Correlation coefficients between the hydration status parameters and those HRV indices that reached statistical significance for all 69 patients enrolled in the
study. Significant values are indicated in bold.
*Spearman p-value < 0.01, #p-value < 0.05, §Pearson p-value < 0.05.
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compare different type of treatment [37]. All these studies
showed that a reduced HRV is an independent prognostic
value of mortality and that HRV analysis permits to iden-
tify alterations in autonomic control, such in unstable pa-
tients. Furthermore, a recent study showed the midterm
effects of initiation of chronic HD therapy and reported a10 0 10 20 30
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Figure 2 HRV indices that significantly correlated with FO/ECW% index
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Table 3 Values of HRV indices for the two groups of patients
L group H group Mann–Whitney Wilcoxon Ld Hd Lnd Hnd One-way ANOVA
# patients 31 38 11 8 20 30
First 30′HD
SDANN (ms) 27(14,38) 13(9,17) P = 0.001 14(10,41) 14(9,17) 29(22,38)* 13(10,17) P = 0.002
VLF (ms2) 460(291,1052) 227(122,594) P = 0.01 310(223,477) 124(44,300) 614(375,1123) 252(141,622) P = 0.1
HF% 14.8(8.2,23.0) 25.5(11.2,39.0) P = 0.04 23.0(7.4,35.8) 28.8(22.0,53.6) 12.1(8.3,20.6) 21.4(9.9,38.7) P = 0.03
LF% 37.3(25.0,50.0) 43.0(28.6,52.3) P = 0.4 34.3(23.9,40.7) 36.0(30.4,46.1) 43.0(28.6,52.3) 33.1(23.7,45.1) P = 0.7
LF/HF 2.72(1.44,5.17) 2.81(1.72,5.78) P = 0.1 1.55(0.83,3.11) 1.53(0.61,2.12) 2.81(1.72,5.78) 2.04(0.87,3.41) P = 0.8
LZC (3,0.001) 0.88(0.85,0.94) 0.83(0.76,0.91) P = 0.07 0.87(0.86,0.92) 0.81(0.77,0.92) 0.88(0.84,0.95) 0.84(0.74,0.91) P = 0.6
Last 30′ HD
SDANN (ms) 17(13,27) 20(13,35) P = 0.1 15(13,21) 12(10,16) 20(13,35) 13(9,31) P = 0.3
VLF (ms2) 634(394,2082) 795(459,2167) P = 0.2 504(372,671) 246(30,860) 795(459,2167) 460(202,1645) P = 0.6
HF% 12.41(9.04,20.57) 11.41(8.12,19.20) P = 0.5 16.06(9.69,26.27) 27.03(19.23,31.04) 11.41(8.12,19.20) 14.80(3.66,27.97) P = 0.5
LF% 41.61(29.41,54.38) 45.55(36.21,58.68) P = 0.07 38.34(23.62,43.83) 36.41(21.47,49.94) 45.55(36.21,58.68) 31.72(16.36,49.99) P = 0.1
LF/HF 2.66(1.74,6.28) 4.09(2.37,7.51) P = 0.09 1.86(1.59,3.50) 1.01(0.39,2.02) 4.09(2.37,7.51) 2.37(1.03,5.70) P = 0.1
LZC (3,0.001) 0.91(0.86,0.95) 0.91(0.88,0.94) P = 0.08 0.93(0.85,0.96) 0.88(0.79,0.97) 0.91(0.88,0.94) 0.87(0.76,0.92) P = 0.2
Entire HD
SDANN (ms) 44(31,62) 28(20,42) P = 0.002 42(30,61)§ 24(21,27) 46(30,61)§ 31(18,45) P = 0.004
VLF (ms2) 675(369, 1627) 415(207,1026) P = 0.09 417(287, 697) 266(61,580) 972(411, 1851) 452(252,1160) P = 0.5
HF% 16.0(7.0,21.6) 16.9(9.5,29.1) P = 0.3 20.9(13.5, 23.8) 23.0(19.3,33.9) 12.7(6.8,18.1) 14.7(6.9,29.1) P = 0.1
LF% 37.88(23.20,53.31) 38.52(22.30,54.50) P = 0.3 37.09(23.20,46.30) 36.99(23.20,44.85) 38.52(22.30,54.50) 30.94(21.45,47.65) P = 0.7
LF/HF 3.07(1.55,5.13) 3.41(1.77,5.30) P = 0.09 2.04(1.15,3.88) 1.18(0.56,1.99) 3.41(1.77,5.30) 2.57(0.90,4.79) P = 0.6
LZC (3,0.001) 0.90(0.86,0.93) 0.86(0.78,0.92) P = 0.1 0.90(0.88,0.91) 0.91(0.78,0.95) 0.90(0.86, 0.94) 0.85(0.78,0.91) P = 0.3
Values of SDANN, VLF, HF% and LZC estimated during the first 30 min of the HD session and for the entire HD session. The values are expressed as median (25°, 75° percentiles). Significant values are indicated in bold.
L group: FOpre ≤ 2.5 L; H group: FOpre > 2.5 L; d: diabetic; nd: non diabetic.
Post-hoc comparisons between the four subgroups (Ld vs Lnd, Hd vs Hnd): § P = 0.02 * P = 0.001.
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Figure 3 Diabetes stratified results for FO/ECW% correlations with HRV indices. Diabetes stratified results for FO/ECW% correlations with
SDANN, LF% and LZC (2,0.05) indices estimated during the last 30 min of HD treatment (panel A, B and C respectively). Regression lines are
portrayed for diabetic patients (D pts) and non-diabetic patients (non D pts) separately. Statistically significant correlations were only obtained for
non-diabetic patients and the correlation coefficients of SDANN, LF% and LZC (2,0.05) indices were r = –0.32, r = –0.43 and r = –0.34, respectively.
The histograms of HRV parameter distributions are shown on the left of each panel.
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significantly correlated with FO when computed during
whole dialysis session. These results support the hy-
pothesis that FO may be associated with reduced HRV,
likely because of heart functional changes induced by
FO. Moreover, FO correlated positively with HF% spec-
tral power during the whole treatment and negatively
with LF during the last 30 minutes of the session. HF
power reflects vagal and respiratory mediated changes
in heart rate, whereas LF power is mostly a marker of
sympathetic modulation [13]. According to these re-
sults, FO may be associated with reduction in the lowTable 4 Data and comorbidities of the five patients followed
Patient ID Sex Vintage Age Diabetes
223 M 6 84 N
2400 F 6 45 N
1318 M 13 73 N
6794 M 1 72 N
1400 F 8 47 N
N = no Y = yes; LVH: left ventricular hypertrophy; PVD: peripheral vascular disease; Coscillatory frequency, i.e. a reduced sympathetic re-
sponse to the HD session. LF% index, which is related
to the sympathetic activation, was inversely correlated
to FO in the last 30 minutes of the treatment (Table 2,
Figure 3B). Sympathetic response to HD is related to
the fluid status of the patient [15], and it involves both
the activation of baroreceptor reflex and peripheral
vasoconstriction. A reduction of circulating blood vol-
ume, caused by the ultrafiltration process, produces a
reduction of arterial transmural pressure and thus of
peripheral vascular resistance (PVR), which may be
sensed by arterial baroreceptors and trigger sympatheticup for 3 months post-study
LVH PVD CHF CAD Arrhythmias
Y Y N N N
Y N N N N
N N N N Y
N N N N N
Y N Y N Y
HF: congestive heart failure; CAD: coronary artery disease.
Table 5 HRV values obtained during the follow-up study
LF (ms2) LF% SDANN (ms)
Patient ID BL 1 M 3 M BL 1 M 3 M BL 1 M 3 M
223 1033.6 271 245.4 55.6 52.9 38.4 47.3 29 57
2400 2938 1101.5 284.3 68.4 47.1 36.3 48.5 70.3 68.7
1318 955.3 622.9 730.5 51.3 43.9 47.9 27.5 29.8 31.6
6794 6.7 227.4 49.5 1.9 39 20.1 34.8 31.1 101.8
1400 151.6 144 82.3 28.2 39 23.8 32.7 91.4 157.9
955.3
(115.4,1509.7)
271.0
(206.6,742.5)
245.4
(74.1,395.9)
51.3
(21.6,58.8)
43.9
(39.0,48.5)
36.3
(22.9,40.8)
34.8
(31.4,47.6)
31.1
(29.6,75.6)
68.7
(50.6,115.8)*
SDANN, LF component and LF% indexes measured during the HD session are shown for each patient at the start (baseline, BL), after 1 month (1 M), when the
hydration target was planned to be reached, and after 3 months (3 M). The last row shows the values of median (25°, 75° percentiles).
*Paired Wilcoxon signed test p-value = 0.06 (3 M vs. BL).
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autonomic response should be to maintain the arterial
blood pressure.
Patients were divided in two groups according to their
hydration state, using 2.5 L as the threshold [20,21]. At
various times during treatment, SDANN, and VLF were
lower in patients of group H (FO > 2.5 L) compared to
group L (FO < 2.5 L), while HF% was instead higher in
the H group compared to the L group (Table 3). There
was also a trend towards lower LF% measured during
the last 30 minutes of HD for the H group versus the L
group. These results are in line with the hypothesis that
FO may be associated with decreased HRV, and a higher
parasympathetic activation, which may prevail on sym-
pathetic response to HD session.
The vintage of group H patient was significantly longer
than in group L. The effect of vintage on overhydration
wasn’t yet investigated, but recently the work of Lindberger
et al. [39] showed that the cognitive profiles seem to have a
key role in the fluid control in patients on HD independ-
ently from the dialysis history. Therefore vintage is sup-
posed not to be a determinant of the overhydration.
In patients with diabetic neuropathy, a reduction of HRV
time-domain parameters has been demonstrated to be not
only of negative prognostic value, but also to precede clin-
ical signs of autonomic dysfunction [40,41]. Hence, patients
were also divided in two groups according to diabetes mel-
litus status. In non-diabetic subjects, HRV indices signifi-
cantly correlated with FO, as observed previously for the
whole population. No such correlations were observed for
patients with diabetes. This can be explained by diabetic
neuropathy, which per se affects the autonomic nervous
system [40], thus masking possible effects of FO. In fact,
the effect of diabetes is a reduction of the absolute power of
LF and HF, as observed in the general population [42].
In the post-study follow up, the FO of five non-diabetic
patients having a predialysis FO greater than 3 liters was
gradually reduced over one month, and then maintained
over the two following months. After this strict control of
fluid, an increase in SDANN index was observed in allpatients, indicating an increase in HRV and an improve-
ment in autonomic heart rate control. Moreover, an im-
portant decrease in LF and LF% was observed in four
patients, and this was more pronounced in patients with
higher baseline values. Furthermore, three out of these
four patients were affected by left ventricular hyper-
trophy, which is known to be associated to sympathetic
overactivity [43]. FO reduction was hypothesized to a
positive effect on cardiac hypertrophy and a blunting ef-
fect on the sympathetic nervous system. Indeed, recent
results have shown that a central inhibition of the sym-
pathetic ANS rapidly reverses cardiac hypertrophy and
problems associated with primary LV relaxation [43,44].
In one patient, LF and LF% did not decrease with the re-
duction of FO. This patient presented very low baseline
values of LF and LF%, and this maybe related to the ab-
sence of LVH, to several arrhythmic events during
hemodialysis and a slight bradycardia (~58 bpm).
Blood pressure control improved with the progressive
reduction of fluid overload, as reflected in the reduction
in DBP after 3 months of strict fluid management. The
reduction of fluid overload and the associated decrease
in sympathetic overactivity may have also stimulated a
reduction in peripheral vascular resistance [43].
The obtained results and the observations collected in
the post study follow-up reinforce the opinion that
chronic volume overload is an important parameter to be
carefully monitored as it is associated to mortality risk and
to alteration of ANS, such sympathetic overactivity and
low HRV. The effect of normalizing FO on ANS can be
evaluated by means of a low cost examination, such as an
ECG Holter. As a matter of fact a more appropriate man-
agement of fluid withdrawal during dialysis can translate
in a better prognosis [45].
Study limitation
The sample size didn’t permit to consider all the possible
confounding factors, such as types of drugs. The comor-
bidities can represent another important confounding ef-
fect too. Only a subset of indices resulted significant,
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cofounding factors or these indices are the only ones asso-
ciated to HD response. Finally, the post study follow up
was limited to 5 patients only, and these findings must be
considered explorative only.
Conclusions
Our results demonstrated for the first time a correlation
between HRV indices and FO: reduced HRV was associ-
ated with higher values of FO. A reduction of FO seems to
positively affect sympathetic ANS activity and HRV in a
small group of patients starting with persistent and clear
FO. Further studies on a larger population and with a lon-
ger follow up are needed to confirm these preliminary
findings and to determine the long-term effects of these
modifications.
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